Ronald Jay Hinklin

This inventor holds 31 USPTO granted patents and 10 published patent applications, plus 4 CIPO patents and 12 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Array Biopharma Inc., Eli Lilly and Company, Mirati Therapeutics, Inc.. Active years: 2005-2025.

USPTO Granted Patents = 31 (Patent Applications = 10)

% Patents Active = 45.2

CIPO Patents = 4 (Patent Applications = 3)

EPO Patents = 12 (Patent Applications = 16)

Average Co-Inventor Count = 8.1

ph-index = 5

Forward Citations = 93(Granted Patents)

Location History:

Boulder, CO (US) (2014 - 2023)
Longmont, CO (US) (2005 - 2024)

Company Filing History:

Eli Lilly and Company

patents

3 out of 44

Mirati Therapeutics, Inc.

Wisconsin Alumni Research Foundation

patents

where one patent can have more than one assignee

Years Active: 2005-2025

Loading Chart...

Areas of Expertise:

Protein Tyrosine Phosphatase Inhibitors

KRAS G12C Inhibitors

Glucokinase Activators

Janus Kinase Inhibitors

Selective Estrogen Receptor Modulators

Pyridin-2-yl-amino Derivatives

Bicyclic Fused Pyridine Compounds

11-Beta-Hydroxysteroid Dehydrogenase Inhibitors

Pyrazolo Compounds

Chemical Synthesis

Piperidinyl-Substituted Lactams

Pentacyclic Oxepines

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12187721 - Protein tyrosine phosphatase inhibitors (2025-01-07),

2. 11884664 - Protein tyrosine phosphatase inhibitors (2024-01-30),

3. 11780835 - Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases (2023-10-10),

4. 11634417 - Protein tyrosine phosphatase inhibitors (2023-04-25),

5. 11267812 - KRAS G12C inhibitors (2022-03-08),

6. 11247990 - Bicyclic fused pyridine compounds as inhibitors of TAM kinases (2022-02-15),

7. 11104676 - Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases (2021-08-31),

8. 11028093 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2021-06-08),

9. 10730880 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as Janus kinase inhibitors (2020-08-04),

10. 10633381 - KRas G12C inhibitors (2020-04-28),

11. 10189845 - 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors (2019-01-29),

12. 10125134 - KRas G12C inhibitors (2018-11-13),

13. 9079890 - Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives (2015-07-14),

14. 8933077 - Glucokinase activators (2015-01-13),

15. 8883828 - 2-aminopyridine analogs as glucokinase activators (2014-11-11),

Title: The Innovative Mind of Ronald Jay Hinklin

Introduction: Ronald Jay Hinklin, a prolific inventor based in Longmont, Colorado, has made significant contributions to the field of biochemistry and pharmaceuticals. With a remarkable portfolio of 31 patents, he has focused primarily on developing compounds that show promise in treating hyperproliferative diseases, demonstrating a commitment to innovation and healthcare advancement.

Latest Patents: Among his latest patents, Hinklin has developed Protein Tyrosine Phosphatase Inhibitors. These patents disclose compounds of Formula Ia or a stereoisomer, tautomer, prodrug, or pharmaceutically acceptable salt thereof, which are particularly useful in the treatment of various hyperproliferative diseases. The methods for utilizing these compounds for diagnosis, prevention, or treatment of such disorders in mammalian cells are detailed comprehensively in his patents, showcasing his thorough approach to pharmaceutical innovation.

Career Highlights: Hinklin's career has included notable tenures at prestigious companies such as Array Biopharma Inc. and Eli Lilly and Company. His work in these organizations has been instrumental in developing pharmaceuticals that address critical health challenges. His deep expertise has not only contributed to the success of these companies but has also significantly advanced the field of medicinal chemistry.

Collaborations: Throughout his career, Hinklin has collaborated with distinguished colleagues such as Mark Joseph Chicarelli and Thomas Daniel Aicher. These partnerships have fostered a dynamic exchange of ideas and innovations, further enhancing his research and contributions to the sector.

Conclusion: Ronald Jay Hinklin's innovative spirit and dedication to advancing medical science through his patents make him a prominent figure in the realm of biopharmaceuticals. His work continues to influence the development of effective treatments for hyperproliferative diseases, affirming his role as a vital contributor to the ongoing quest for medical breakthroughs.